![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Anti-Fibrotic and Anti-Inflammatory Activity of the Dual CCR2 and CCR5 Antagonist Cenicriviroc in a Mouse Model of NASH
|
|
|
Reported by Jules Levin
AASLD 2013 Nov 1-5 Wash DC
E. Lefebvre1, T. Hashiguchi2, H. Jenkins1,
H. Yoneyama2, S.L. Friedman3, G.H.I. Wolfgang4
1Tobira Therapeutics, Inc., San Francisco, CA, USA; 2Stelic Institute & Co., Tokyo, Japan;
3Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, NY, USA; 4Kailua-Kona, HI, USA
![AASLD1.gif](../images/121113/121113-3/AASLD1.gif)
![AASLD2.gif](../images/121113/121113-3/AASLD2.gif)
![AASLD3.gif](../images/121113/121113-3/AASLD3.gif)
![AASLD4.gif](../images/121113/121113-3/AASLD4.gif)
![AASLD5.gif](../images/121113/121113-3/AASLD5.gif)
![AASLD6.gif](../images/121113/121113-3/AASLD6.gif)
![AASLD8.gif](../images/121113/121113-3/AASLD8.gif)
![AASLD9.gif](../images/121113/121113-3/AASLD9.gif)
![AASLD10.gif](../images/121113/121113-3/AASLD10.gif)
![AASLD11.gif](../images/121113/121113-3/AASLD11.gif)
![AASLD12.gif](../images/121113/121113-3/AASLD12.gif)
![AASLD13.gif](../images/121113/121113-3/AASLD13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|